Bernard Taverne, Alice Desclaux, Papa Salif Sow

CHAPITRE I-1Mortalité : incidence, causes et facteurs de risqueird-00718213, version 1 - 16 Jul 201217. Gupta A, Nadkarni G, Yang WT, Chandrasekhar A, Gupte N,Bisson GP, et al. Early mortality in adults initiating antiretroviral therapy(ART) in low- and middle-income countries (LMIC): a systematicreview and meta-analysis. PLoS One. 2011;6(12):e28691.18. Etard JF, Ndiaye I, Thierry-Mieg M, Guèye NF, Guèye PM,Lanièce I, et al. Mortality and causes of death in adults receivinghighly active antiretroviral therapy in Senegal: a 7-year cohortstudy. AIDS. 2006 May 12;20(8):1181-9.19. Seyler C, Anglaret X, Dakoury-Dogbo N, Messou E, Touré S,Danel C, et al; ANRS 1203 Study Group. Medium-term survival,morbidity and immunovirological evolution in HIV-infected adultsreceiving antiretroviral therapy, Abidjan, Côte d'Ivoire. Antivir Ther.2003 Oct;8(5):385-93.20. Kadhiravan T, Sharma SK. Mortality of HIV-infected patients inlow-income countries. Lancet. 2006 Dec 23;368(9554):2207;author reply 2207-8.21. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A,Miotti P, et al; Antiretroviral Therapy in Lower Income Countries(ART-LINC) Collaboration; ART Cohort Collaboration (ART-CC)groups. Mortality of HIV-1-infected patients in the first year ofantiretroviral therapy: comparison between low-income andhigh-income countries. Lancet. 2006 Mar 11;367(9513):817-24.Erratum in: Lancet. 2006 Jun 10;367(9526):1902.22. Kumarasamy N, Venkatesh KK, Devaleenol B, Poongulali S,Yephthomi T, Pradeep A, et al. Factors associated with mortalityamong HIV-infected patients in the era of highly active antiretroviraltherapy in southern India. Int J Infect Dis. 2010 Feb;14(2):e127-31.23. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Earlymortality among adults accessing antiretroviral treatment programmesin sub-Saharan Africa. AIDS. 2008 Oct 1;22(15):1897-908.24. Etard JF, Le Hesran JY, Diallo A, Diallo JP, Ndiaye JL, DelaunayV. Childhood mortality and probable causes of death usingverbal autopsy in Niakhar, Senegal, 1989–2000. Int J Epidemiol2004; 33:1286–1292.25. WHO. Antiretroviral therapy for HIV infection in adults and adolescents,Recommendations for a public health approach, 2010 Revision.Disponible à partir de: URL: http://www.who.int/hiv/pub/arv/adult2010/en/index.html (consulté le 10/05/2012).26. Brinkhof MW, Boulle A, Weigel R, Messou E, Mathers C, OrrellC, et al; International Epidemiological Databases to Evaluate AIDS(IeDEA). Mortality of HIV-infected patients starting antiretroviraltherapy in sub-Saharan Africa: comparison with HIV-unrelatedmortality. PLoS Med. 2009 Apr 28;6(4):e1000066.27. MacPherson P, Moshabela M, Martinson N, Pronyk P. Mortalityand loss to follow-up among HAART initiators in rural South Africa.Trans R Soc Trop Med Hyg. 2009 Jun;103(6):588-93.28. Pacheco AG, Tuboi SH, May SB, Moreira LF, Ramadas L,Nunes EP, et al. Temporal changes in causes of death amongHIV-infected patients in the HAART era in Rio de Janeiro, Brazil. JAcquir Immune Defic Syndr. 2009 Aug 15;51(5):624-30.29. Melo LS, Lacerda HR, Campelo E, Moraes E, Ximenes RA.Survival of AIDS patients and characteristics of those who died overeight years of highly active antiretroviral therapy, at a referral centerin northeast Brazil. Braz J Infect Dis. 2008 Aug;12(4):269-77.30. Corey DM, Kim HW, Salazar R, Illescas R, Villena J, GutierrezL, et al. Brief report: effectiveness of combination antiretroviraltherapy on survival and opportunistic infections in a developingworld setting: an observational cohort study. J Acquir ImmuneDefic Syndr. 2007 Apr 1;44(4):451-5.31. Bisson GP, Gaolathe T, Gross R, Rollins C, Bellamy S, MogorosiM, Avalos A, Friedman H, Dickinson D, Frank I, Ndwapi N.Overestimates of survival after HAART: implications for globalscale-up efforts. PLoS One. 2008 Mar 5;3(3):e1725.32. de Boer-van der Kolk IM, Sprangers MA, Prins JM, Smit C, de WolfF, Nieuwkerk PT. Health-related quality of life and survival amongHIV-infected patients receiving highly active antiretroviral therapy: astudy of patients in the AIDS Therapy Evaluation in the Netherlands(ATHENA) Cohort. Clin Infect Dis. 2010 Jan 15;50(2):255-63.33. Uhlenkott MC, Buskin SE, Kahle EM, Barash E, Aboulafia DM.Causes of death in the era of highly active antiretroviral therapy: aretrospective analysis of a hybrid hematology-oncology and HIVpractice and the Seattle/King county adult/adolescent spectrum ofHIV-related diseases project. Am J Med Sci. 2008 Sep;336(3):217-23.34. Data Collection on Adverse Events of Anti-HIV drugs (D:A:D)Study Group, Smith C, Sabin CA, Lundgren JD, Thiebaut R,Weber R, et al. Factors associated with specific causes of deathamongst HIV-positive individuals in the D:A:D Study. AIDS. 2010Jun 19;24(10):1537-48. Erratum in: AIDS. 2011 Mar 27;25(6):883.35. Lau B, Gange SJ, Moore RD. Risk of non-AIDS-related mortalitymay exceed risk of AIDS-related mortality among individualsenrolling into care with CD4+ counts greater than 200 cells/mm3. JAcquir Immune Defic Syndr. 2007 Feb 1;44(2):179-87.36. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of deathamong persons with AIDS in the era of highly active antiretroviraltherapy: New York City. Ann Intern Med. 2006 Sep 19;145(6):397-406.37. Strategies for Management of Antiretroviral Therapy (SMART)Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F,Abrams D, et al. CD4+ count-guided interruption of antiretroviraltreatment. N Engl J Med. 2006 Nov 30;355(22):2283-96.38. De Beaudrap P, Etard JF, Diouf A, Ndiaye I, Guèye NF, GuèyePM, et al; ANRS 1215/90 Study Group. Modeling CD4+ cell countincrease over a six-year period in HIV-1-infected patients on highlyactive antiretroviral therapy in Senegal. Am J Trop Med Hyg. 2009Jun;80(6):1047-53.39. Neuhaus J, Angus B, Kowalska JD, La Rosa A, Sampson J,Wentworth D, et al; INSIGHT SMART and ESPRIT study groups.Risk of all-cause mortality associated with nonfatal AIDS andserious non-AIDS events among adults infected with HIV. AIDS.2010 Mar 13;24(5):697-706.40. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, etal. Risk of myocardial infarction in patients with HIV infectionexposed to specific individual antiretroviral drugs from the 3 majordrug classes: the data collection on adverse events of anti-HIVdrugs (D:A:D) study. J Infect Dis 2010; 201:318–330.41. Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptaseinhibitors and risk of myocardial infarction in HIV-infectedpatients. AIDS 2008; 22:F17–F24.42. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M,et al. Estimated glomerular filtration rate, chronic kidney diseaseand antiretroviral drug use in HIV-positive patients. AIDS 2010;24:1667–1678.43. McMahon J, Wanke C, Terrin N, Skinner S, Knox T. Poverty,hunger, education, and residential status impact survival in HIV.AIDS Behav. 2011 Oct;15(7):1503-11.44. Liotta G, Caleo GM, Mancinelli S. Analysis of survival in HIV-infectedsubjects according to socio-economic resources in theHAART era. Ann Ig. 2008 Mar-Apr;20(2):95-104.45. Borrell C, Rodríguez-Sanz M, Pasarín MI, Brugal MT, Garcíade-OlallaP, Marí-Dell'Olmo M, et al. AIDS mortality before andafter the introduction of highly active antiretroviral therapy: does itvary with socioeconomic group in a country with a National HealthSystem? Eur J Public Health. 2006 Dec;16(6):601-8.46. Rapiti E, Porta D, Forastiere F, Fusco D, Perucci CA. Socioeconomicstatus and survival of persons with AIDS before and afterthe introduction of highly active antiretroviral therapy. Lazio AIDSSurveillance Collaborative Group. Epidemiology. 2000Sep;11(5):496-501.47. Petoumenos K, Law MG; Australian HIV ObservationalDatabase. Risk factors and causes of death in the Australian HIVObservational Database. Sex Health. 2006 May;3(2):103-12.48. Falster K, Choi JY, Donovan B, Duncombe C, Mulhall B,Sowden D, et al; Australian HIV Observational Database; TREATAsia HIV Observational Database. AIDS-related and non-AIDS-relatedmortality in the Asia-Pacific region in the era of combinationantiretroviral treatment. AIDS. 2009 Nov 13;23(17):2323-36.14